Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study

BACKGROUND: Patients presenting with early-stage melanoma (AJCC pT1b-pT2a) reportedly have a relatively low risk of a positive SNB (~5–10%). Those patients are usually found to have low-volume metastatic disease after SNB, typically reclassified to AJCC stage IIIA, with an excellent prognosis of ~90...

Descripción completa

Detalles Bibliográficos
Autores principales: Moncrieff, Marc D., Lo, Serigne N., Scolyer, Richard A., Heaton, Martin J., Nobes, Jenny P., Snelling, Andrew P., Carr, Michael J., Nessim, Carolyn, Wade, Ryckie, Peach, A. Howard, Kisyova, Rumi, Mason, Jennifer, Wilson, Ewan D., Nolan, Grant, Pritchard Jones, Rowan, Sondak, Vernon K., Thompson, John F., Zager, Jonathan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Melanoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356930/
https://www.ncbi.nlm.nih.gov/pubmed/35562521
http://dx.doi.org/10.1245/s10434-022-11761-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356930/
https://www.ncbi.nlm.nih.gov/pubmed/35562521
http://dx.doi.org/10.1245/s10434-022-11761-4

Ejemplares similares